<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-02-06</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-02-06 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">105</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-02-07 04:07</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-31">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/31</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-02-01">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">02/01</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-02">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">02/02</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-03">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">02/03</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-04">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">02/04</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-05">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">02/05</span>
            </button>
            
            <button class="date-btn " data-filter="2026-02-06">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">02/06</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šç„¦ç‚¹é›†ä¸­åœ¨GLP-1è¯ç‰©å¸‚åœºçš„æ¿€çƒˆç«äº‰ä¸ç›‘ç®¡å†²çªï¼Œä»¥åŠç”Ÿç‰©ç§‘æŠ€IPOå¸‚åœºçš„æ˜¾è‘—å¤è‹ã€‚FDAå±€é•¿å…¬å¼€è­¦å‘Šå°†æ‰“å‡»Hims & Hersç­‰å…¬å¸å¯¹Wegovyä»¿åˆ¶ç‰ˆçš„å¤§è§„æ¨¡è¥é”€ï¼Œå¼•å‘è¡Œä¸šå¯¹åˆè§„é£é™©çš„å…³æ³¨ã€‚åŒæ—¶ï¼Œå¤šå®¶AIé©±åŠ¨å’Œç”Ÿç‰©ç§‘æŠ€å…¬å¸æˆåŠŸè¿›è¡ŒIPOï¼Œæ˜¾ç¤ºèµ„æœ¬å¸‚åœºå¯¹åˆ›æ–°ç–—æ³•çš„ä¿¡å¿ƒå›æš–ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>2. FDA's Makary pledges crackdown on mass marketing of 'illegal copycat drugs' in wake of Hims' Wegovy pill push</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: æ”¿ç­–æ³•è§„<br>
   - FDAå±€é•¿å…¬å¼€è¡¨æ€å°†ä¸¥å‰æ‰“å‡»GLP-1è¯ç‰©ä»¿åˆ¶ç‰ˆçš„å¤§è§„æ¨¡è¥é”€ï¼Œç›´æ¥å½±å“å‡è‚¥è¯å¸‚åœºç«äº‰æ ¼å±€ä¸åˆè§„ç¯å¢ƒã€‚</p>
<p><strong>13. Him & Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - Hims & Hersæ¨å‡ºä½ä»·Wegovyä»¿åˆ¶ç‰ˆå¼•å‘è¯ºå’Œè¯ºå¾·æ³•å¾‹å¨èƒï¼Œå‡¸æ˜¾GLP-1å¸‚åœºå®šä»·æˆ˜ä¸çŸ¥è¯†äº§æƒå†²çªã€‚</p>
<p><strong>1. Flagship's Generate:Biomedicines files for IPO, pitching AI-driven drugs</strong> â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - AIç”Ÿç‰©æŠ€æœ¯é¢†å†›ä¼ä¸šåœ¨IIIæœŸè¯•éªŒå¯åŠ¨åè¿…é€Ÿç”³è¯·IPOï¼Œåæ˜ èµ„æœ¬å¸‚åœºå¯¹AIé©±åŠ¨è¯ç‰©ç ”å‘çš„é«˜åº¦å…³æ³¨ã€‚</p>
<p><strong>25. Agomab, SpyGlass cap biggest week for biotech IPOs since 2021</strong> â­â­â­â­<br>
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€<br>
   - ç”Ÿç‰©ç§‘æŠ€IPOè¿æ¥è‡ª2021å¹´ä»¥æ¥æœ€æ´»è·ƒçš„ä¸€å‘¨ï¼Œæ˜¾ç¤ºè¡Œä¸šèèµ„ç¯å¢ƒæ˜¾è‘—æ”¹å–„ã€‚</p>
<p><strong>4. FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill</strong> â­â­â­â­<br>
   - ç±»åˆ«: æ”¿ç­–æ³•è§„<br>
   - æ”¿åºœèµ„åŠ©æ³•æ¡ˆé‡æ–°æˆæƒç½•è§å„¿ç§‘ç–¾ç—…ä¼˜å…ˆå®¡è¯„åˆ¸è®¡åˆ’ï¼Œå°†åŠ é€Ÿå„¿ç«¥ç½•è§ç—…è¯ç‰©å¼€å‘ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): AIé©±åŠ¨è¯ç‰©ç ”å‘å…¬å¸Generate:Biomedicinesæ¨è¿›ç®¡çº¿ï¼›å®‰æ–¯æ³°æ¥æŠ—ç™Œè¯Vyloyé”€å”®è¶…é¢„æœŸï¼›BMSå’ŒGSKå¼ºè°ƒä»¥äº§å“ä¸ºæ ¸å¿ƒçš„ç ”å‘ç­–ç•¥ã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): Generate:Biomedicinesåœ¨IIIæœŸè¯•éªŒç»™è¯åè¿…é€Ÿç”³è¯·IPOï¼›BMSè¿‘æœŸå°†æœ‰è‡³å°‘10é¡¹å…³é”®ä¸´åºŠæ•°æ®è¯»å‡ºï¼ŒææŒ¯ç®¡çº¿ä¿¡å¿ƒã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>é‡ç‚¹å…³æ³¨FDAå¯¹Hims & Herså¤åˆç‰ˆWegovyçš„ç›‘ç®¡è¡ŒåŠ¨è¿›å±•ï¼Œä»¥åŠè¯ºå’Œè¯ºå¾·å¯èƒ½é‡‡å–çš„æ³•å¾‹æªæ–½ï¼›åŒæ—¶ç•™æ„ç”Ÿç‰©ç§‘æŠ€IPOå¸‚åœºçš„åç»­è¡¨ç°ï¼Œç‰¹åˆ«æ˜¯Generate:Biomedicinesç­‰å…¬å¸çš„ä¸Šå¸‚åè‚¡ä»·èµ°åŠ¿ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Flagship&#39;s Generate:Biomedicines files for IPO, pitching AI-driven drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 12:00</span>
                        
                        <span class="news-importance">â­â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Just nine days after dosing the first patient in a Phase 3 trial, Generate:Biomedicines has filed for an IPO. The Flagship Pioneering-backed startup has become a richly-funded leader of AI bio since its founding in ...</p>
                    
                    <a href="https://endpoints.news/flagships-generatebiomedicines-files-for-ipo-pitching-ai-driven-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Orphan drug tweak in US spending bill will make life easier for the FDA
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 19:10</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The FDA can continue to grant seven years of exclusivity for orphan drugs with new indications, as President Donald Trump this week signed a government funding extension that included a provision that codifies that process ...</p>
                    
                    <a href="https://endpoints.news/orphan-drug-tweak-in-us-spending-bill-will-make-life-easier-for-the-fda/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eikon IPO analysis: Big biotech names, big valuation cut
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 14:32</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">For Eikon Therapeutics, its IPO feels more like something itâ€™s surviving rather than celebrating. The Bay Area startup is one of biotechâ€™s most prominent privately-held companies, after raising more than $1 billion to advance its ...</p>
                    
                    <a href="https://endpoints.news/eikon-ipo-analysis-big-biotech-names-big-valuation-cut/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 15:22</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Thermo Fisher Scientific is closing its chemical analysis manufacturing site in Franklin, MA, due to â€œcurrent customer demands,â€ a company spokesperson told Endpoints News. Operations there will be phased out by the end of the ...</p>
                    
                    <a href="https://endpoints.news/thermo-fisher-charles-river-workforce-cuts-wuxi-signs-contract-with-vertex/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Agomab, SpyGlass bank a combined $350M in biotech IPOs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-06 00:59</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The two offerings capped off the busiest week for new biotech stock issuances in a year.</p>
                    
                    <a href="https://www.biopharmadive.com/news/agomab-spyglass-biotech-ipo-price-2026/811385/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo, Lilly sputter as Hims launches knockoff GLP-1 pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 17:22</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo is threatening litigation in response, while FDA head Martin Makary, without naming specific companies, said the agency would take &amp;ldquo;swift action&amp;rdquo; against those &amp;ldquo;mass-marketing illegal copycat drugs.&amp;rdquo;&amp;nbsp;&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/hims-compounded-wegovy-glp-1-obesity-novo-lilly/811476/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generate, an AI-driven Flagship startup, pitches an IPO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 16:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.</p>
                    
                    <a href="https://www.biopharmadive.com/news/generate-biomedicines-ipo-flagship-ai-tlsp/811482/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 01:08</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity since early last year.</p>
                    
                    <a href="https://www.biopharmadive.com/news/eikon-biotech-ipo-price-cancer-drugs-2026/811169/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 17:18</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.</p>
                    
                    <a href="https://www.biopharmadive.com/news/trump-signs-legislation-end-partial-government-shutdown-pbm-reform-telehealth-hospital-at-home/811365/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Agomab, SpyGlass cap biggest week for biotech IPOs since 2021
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 16:26</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Biotech IPOs are on the comeback trail. Fibrosis-focused Agomab Therapeutics and eye disease company SpyGlass Pharma will go public on Friday in respective $200 million and</p>
                    
                    <a href="https://endpoints.news/agomab-spyglass-cap-biggest-week-for-biotech-ipos-since-2021/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Illumina bets on healthcare after Trump administration&#39;s NIH funding disruptions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 09:19</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">DNA sequencing company Illumina is leaning more into healthcare after its traditional research market was rattled by the Trump administration&#39;s disruptions to NIH funding. After a string of largely ...</p>
                    
                    <a href="https://endpoints.news/illumina-bets-on-healthcare-after-trump-administrations-nih-funding-disruptions/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA chief Makary takes aim at Hims&#39; compounded Wegovy pill plans
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 23:52</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA Commissioner Marty Makary took a not-so-subtle swipe at Hims &amp;amp; Hers in a social media post Thursday, saying his agency would &#34;take swift action against companies mass-marketing illegal copycat drugs.&#34; Without naming Hims, Makary&#39; ...</p>
                    
                    <a href="https://endpoints.news/fda-chief-makary-takes-aim-at-hims-compounded-wegovy-pill-plans/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Veradermics CEO has a great hair day with 122% pop in IPO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 18:34</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Investors are showing some love to the biotech testing an oral form of Rogaine, betting that people will want good hair too as the aesthetics market surges with direct-to-consumer GLP-1s. Veradermics&#39; stock surged 122% in ...</p>
                    
                    <a href="https://endpoints.news/veradermics-ceo-has-a-great-hair-day-with-122-pop-in-ipo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bristol Myers draws pipeline excitement as several data readouts near
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 15:50</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">For the first time in a while, investors seem excited about Bristol Myers Squibbâ€™s late-stage pipeline. Bristol Myers on Thursday flagged at least 10 potential data readouts coming this year that could lead to new ...</p>
                    
                    <a href="https://endpoints.news/bristol-myers-draws-pipeline-excitement-as-several-data-readouts-near/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Telehealth provider Hims goes after Novo&#39;s weight loss pill with compounded version
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 14:58</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Online healthcare provider Hims &amp;amp; Hers said it would start selling a compounded version of Novo Nordiskâ€™s Wegovy pill on Thursday, just a month after the FDAâ€™s approval of the brand-name pill version of the ...</p>
                    
                    <a href="https://endpoints.news/telehealth-provider-hims-goes-after-novos-weight-loss-pill-with-compounded-version/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Eisai gains Henlius therapy; LB Pharma snags $100M in funding
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 14:21</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <a href="https://endpoints.news/eisai-gains-henlius-therapy-lb-pharma-snags-100m-in-funding/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bayer details anticipated stroke prevention data for new blood-thinner
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 17:15</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Asundexian&amp;nbsp;cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.</p>
                    
                    <a href="https://www.biopharmadive.com/news/bayer-asundexian-factorXIa-secondary-stroke-data-conference/811455/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Geoff McDonough&#39;s big plans for NodThera&#39;s NLRP3; Enhertu leader steps down at Daiichi
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 12:00</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Geoff McDonough is tipping his hat to one of the hottest targets in drug development right now. The former Generation Bio CEO has joined NodThera to get its NLRP3 program into Phase 3 next year ...</p>
                    
                    <a href="https://endpoints.news/geoff-mcdonoughs-big-plans-for-nodtheras-nlrp3-enhertu-leader-steps-down-at-daiichi/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roivant spinout Priovant touts Phase 2 brepocitinib data in cutaneous sarcoidosis
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 12:00</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Priovant Therapeutics, a Roivant spinout, announced that an experimental immune drug it inherited from Pfizer succeeded in a Phase 2 trial for cutaneous sarcoidosis, a rare condition that causes small bumps or ...</p>
                    
                    <a href="https://endpoints.news/roivant-spinout-priovant-touts-phase-2-brepocitinib-data-in-cutaneous-sarcoidosis/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #ISC26: Bayerâ€™s asundexian reduced ischemic strokes by 26% in Phase 3 trial
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 17:15</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bayer shared more details from its unexpected win in a Phase 3 study testing its next-generation blood thinner for secondary stroke prevention. The factor XIa inhibitor, named asundexian, reduced the occurrence of ischemic stroke by ...</p>
                    
                    <a href="https://endpoints.news/isc26-bayers-asundexian-reduced-ischemic-strokes-by-26-in-phase-3-trial/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Angitia gets $130M Series D for pipeline of musculoskeletal drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 12:30</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A US-China biotech has reeled in $130 million for three biologics in clinical testing for musculoskeletal diseases, including one in which Ultragenyx recently came up short. Angitia Biopharmaceuticals disclosed its Series D ...</p>
                    
                    <a href="https://endpoints.news/angitia-gets-130m-series-d-for-pipeline-of-musculoskeletal-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        White Houseâ€™s online service for drug sales debuts with limited impact on prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-06 17:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won&amp;rsquo;t be felt by many Americans whose medications are covered by insurance.</p>
                    
                    <a href="https://www.biopharmadive.com/news/trump-rx-drug-prices-discount-white-house/811576/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Earnings roundup: AbbVie angst, a bifurcated vaccine market and Bristol Myersâ€™ waiting game
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 21:32</span>
                        
                    </div>
                    
                    <p class="news-summary">Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie franchise and Bristol Myers pointed to a trio of narrative-changing trials.</p>
                    
                    <a href="https://www.biopharmadive.com/news/bristol-myers-abbvie-gsk-vaccines-biotech-earnings-q4-2025/811463/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Express Scripts reaches â€˜landmarkâ€™ settlement with FTC in insulin suit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-05 11:46</span>
                        
                    </div>
                    
                    <p class="news-summary">The agreement announced Wednesday includes sweeping changes to the Cigna PBM&amp;rsquo;s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.</p>
                    
                    <a href="https://www.biopharmadive.com/news/express-scripts-ftc-reach-settlement-insulin-lawsuit/811436/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo shares tumble by double digits on grim sales outlook
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-02-04 16:55</span>
                        
                    </div>
                    
                    <p class="news-summary">In contrast to Lilly&amp;rsquo;s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/novo-nordisk-2025-earnings-2026-outlook/811318/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        US calls for DOJ investigation of Hims over GLP-1 drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 23:08</span>
                        
                    </div>
                    
                    <p class="news-summary">The US government said it will refer telehealth and GLP-1 company Hims &amp;amp; Hers to the Department of Justice for investigation, following the company&#39;s controversial launch of a compounded version of Novo ...</p>
                    
                    <a href="https://endpoints.news/us-calls-for-doj-investigation-of-hims-over-glp-1-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        TrumpRx launch falls flat for some, citing generic access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 21:01</span>
                        
                    </div>
                    
                    <p class="news-summary">When President Donald Trump unveiled his anticipated direct-to-consumer drug platform on Thursday, he said he&#39;d done what other politicians had promised but never delivered. &#34;They all failed,â€ he said. â€œIt was all words as usual&#34; ...</p>
                    
                    <a href="https://endpoints.news/trumprx-launch-falls-flat-for-some-citing-generic-access/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        HHS drops legal fight over blocked 340B rebate pilot
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 19:19</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration is taking a step back from its planned 340B rebate pilot that a court blocked last month. HHS asked a Maine federal court to set aside actions related to the original pilot ...</p>
                    
                    <a href="https://endpoints.news/hhs-drops-legal-fight-over-blocked-340b-rebate-pilot/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biogen CEO says Alzheimer&#39;s drug Leqembi on track for continued growth
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 16:11</span>
                        
                    </div>
                    
                    <p class="news-summary">Biogen and Eisai&#39;s Alzheimerâ€™s drug Leqembi appears to have reached some stable growth after a bumpy couple of years. Leqembi generated $134 million in fourth-quarter sales worldwide in 2025, jumping 54% from the previous year ...</p>
                    
                    <a href="https://endpoints.news/biogen-ceo-says-alzheimers-drug-leqembi-on-track-for-continued-growth/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UniQure pauses higher doses in Fabry study; Aro shares Pompe data
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 15:00</span>
                        
                    </div>
                    
                    <p class="news-summary">â¸ï¸ UniQure pauses mid- and high-doses in Fabry gene therapy study: The company reported that two patients who received a 4x1013 genome copies per kilogram (gc/kg) dose faced grade 3 liver enzyme elevations. That comes ...</p>
                    
                    <a href="https://endpoints.news/uniqure-pauses-higher-doses-in-fabry-study-aro-shares-pompe-data/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Post-Hoc Live: Analyzing the Novo vs. Hims GLP-1 showdown
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-06 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">I&#39;ve been waiting for the big showdown between drugmakers and compounders for months, and it&#39;s finally here. Today on Post-Hoc Live at 12 p.m. ET, we&#39;ll be talking about telehealth company Hims &amp;amp; Hers&#39; plan ...</p>
                    
                    <a href="https://endpoints.news/post-hoc-live-analyzing-the-novo-vs-hims-glp-1-showdown/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo&#39;s threat to sue Hims over Wegovy pill faces legal hurdle
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 21:25</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk&#39;s threatened legal action against Hims &amp;amp; Hers for selling a compounded version of the pharma giantâ€™s newly launched Wegovy pill may be far from a slam-dunk win. Dae Lee, an attorney at Buchanan ...</p>
                    
                    <a href="https://endpoints.news/novos-threat-to-sue-hims-over-wegovy-pill-faces-legal-hurdle/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        White House launches TrumpRx
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 20:55</span>
                        
                    </div>
                    
                    <p class="news-summary">The White House on Thursday launched TrumpRx, the long-awaited direct-to-consumer hub that&#39;s a cornerstone of the administrationâ€™s push to lower drug prices. The official unveiling had been months in the making and was slightly delayed ...</p>
                    
                    <a href="https://endpoints.news/white-house-plans-to-launch-trumprx-thursday/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GLP-1s and the Super Bowl
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-02-05 15:41</span>
                        
                    </div>
                    
                    <p class="news-summary">The Super Bowl is once again getting the GLP-1 ad treatment. Hims &amp;amp; Hers is back with another combative spot that calls out the disparities in healthcare experiences between the ...</p>
                    
                    <a href="https://endpoints.news/glp-1s-and-the-super-bowl/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">42 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UPDATE: FDA&#39;s Makary pledges crackdown on mass marketing of &#39;illegal copycat drugs&#39; in wake of Hims&#39; Wegovy pill push
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-06 09:47</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">â€œFDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,â€ FDA commissioner Marty Makary, M.D., said in a Feb. 5 post on X. The comments mark a clear and sharp rebuttal to Himsâ€™ announcement earlier in the day that it had launched a compounded version of Novo Nordiskâ€™s new Wegovy pill for obesity, just weeks after Novo&#39;s own launch.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/after-hims-compounded-wegovy-pill-upset-fdas-makary-pledges-crackdown-mass-marketing-illegal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fierce Pharma Asiaâ€”Amgen, Kyowa&#39;s OX40 divorce; Roche&#39;s RNAi deal; Daiichi&#39;s ADC cull
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 15:16</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche penned a deal worth up to $1.7 billion for an RNA interference program from SanegeneBio. Daiichi Sankyo stopped development of its first non-DXd candidate. And more.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/amgen-kyowa-ox40-divorce-roche-rnai-deal-daiichi-adc-cull" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDAâ€™s rare pediatric disease voucher program revived by 2026 government funding bill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 15:02</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">By signing a government funding bill that ended a partial shutdown, President Donald Trump has also reauthorized a beloved program meant to speed the development of new drugs for rare childhood diseases.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/fdas-rare-pediatric-disease-voucher-program-revived-2026-government-funding-bill" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-07">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: HHS asks Justice Department to probe Hims &amp; Hers over its cheaper compounded version of Wegovy
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-07 01:05</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA will take â€œdecisive stepsâ€ to thwart companies from mass marketing unapproved, compounded versions of GLP-1 drugs</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/06/fda-take-action-against-hims-telehealth-wegovy-compounding/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo adds star-studded first Super Bowl spot to Wegovy pillâ€™s â€˜dramaticâ€™ rollout blitz
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 15:57</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertisingâ€™s biggest stage to help get the word out.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/novo-adds-star-studded-first-super-bowl-ad-wegovy-pills-dramatic-rollout-blitz" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Him &amp;amp; Hers plans to offer cheaper version of Wegovy pill, prompting Novo Nordisk to threaten legal action
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 12:20</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims &amp;amp; Hers plans to undercut it with a compounded semaglutide pill offered at a lower price.</p>
                    
                    <a href="https://www.fiercepharma.com/health-tech/him-hers-plans-offer-cheaper-version-wegovy-pill-prompting-novo-nordisk-threaten-legal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 11:16</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The majority of Bristol Myers Squibb&#39;s $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/stagnating-sales-older-legacy-meds-bms-leans-new-growth-drivers-weather-storm" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Astellas tops expectations as Vyloy sales surge outshines trial setback
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 10:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/astellas-tops-expectations-vyloy-sales-surge-outshines-trial-setback" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        A cut above: Veradermics locks in $256M IPO and shares spike
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 09:43</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according to a Securities and Exchange Commission filing. Veradermics is trading under the symbol &#34;MANE.&#34;</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/cut-above-hair-regrowth-biotech-veradermics-locks-oversubscribed-256m-ipo" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Eli Lilly said it will be impacted by pricing pressures in 2026 for its juggernaut products Mounjaro and Zepbound. But the company&#39;s momentum is such that it still expects revenues to reach between $80 billion and $83 billion, which would be a 25% increase from 2025 sales at the midpoint.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AbbVie, hitting record sales on Skyrizi gains, holds its own in growing IBD arena despite J&amp;amp;J competition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:08</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">AbbVie&#39;s immunology drug portfolio of Skyrizi, Rinvoq and older Humira contributed $30.4 billion to the company&#39;s yearly haul of $61.1 billion.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/abbvie-hitting-record-sales-high-skyrizi-gains-holds-its-own-growing-ibd-arena-despite-jj" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        As CEO, Luke Miels wants GSK to be more &#39;product-centric&#39;
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 09:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In his first investor update as GSKâ€™s CEO, Luke Miels defined a core of his vision for the companyâ€™s next chapter: â€œWe need to be more product-centric as a company.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/ceo-luke-miels-wants-gsk-be-more-product-centric" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: IPOs, GLP-1s, and challenges with a gene therapy
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-06 14:19</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/06/biotech-news-trumprx-launches-and-roivant-scores-a-win/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 14:25</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Based on ads released in advance of the Super Bowl, little has changed in the eyes of the pharma industry since the FDA began a &#34;crackdown&#34; on drug marketing</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/05/fda-ftc-pbm-super-bowl-teva-autism-layoffs-vertex-amgen/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The FDA wants to rein in drug ads. On Super Bowl Sunday, it will be business as usual
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 09:30</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">On Super Bowl Sunday, the drug industry is trotting out lounging football stars, a shouting DJ Khaled, and the soothing tones of Enya.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/drug-ads-super-bowl-sunday-fda/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about worries over FDA voucher program, a new U.S. Novo exec, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 14:09</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA leaders tried to quell concerns about a controversial new program to fast-track certain drugs at an employee town hall meeting</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/04/novo-obesity-trump-psychedelics-fda-vouchers-switzerland/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about a Pfizer obesity pill, Floridaâ€™s failed drug importation plan, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:28</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Pfizer disclosed that an experimental weight loss drug, recently picked up through its acquisition of Metsera, hit its marks in a mid-stage study</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/03/pfizer-obesity-florida-gsk-animals-kennedy-astrazeneca-novarits/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BMS celebrates US soccer legend&#39;s shutout against cancer in Breyanzi collab
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 11:20</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Bristol Myers Squibb has signed Kasey Keller for a Breyanzi partnership, giving the U.S, Soccer Hall of Famer a platform to discuss how the CD19-directed CAR-T cell therapy blocked the recurrence of his non-Hodgkin lymphoma.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/bristol-myers-celebrates-us-soccer-legends-shutout-against-cancer-breyanzi-ad" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        OXB expands BMS partnership to churn out lentiviral vectors for commercial CAR-Ts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 09:47</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giantâ€™s CAR-T programs.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/oxb-expands-bms-partnership-churn-out-lentiviral-vectors-car-t" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly likens relentless work of scientific and athletic progress in Winter Olympics ad
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-06 12:26</span>
                        
                    </div>
                    
                    <p class="news-summary">As the 2026 Winter Olympics get underway in Italy this week, Eli Lillyâ€”a partner of both Team USA and the Milan Cortina Games as a wholeâ€”is rolling out a new corporate campaign inspired by the event.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/lilly-likens-relentless-work-scientific-and-athletic-progress-ad-timed-winter-olympics" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rocheâ€™s Genentech cut at least 489 jobs last year, new disclosure reveals
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-06 13:23</span>
                        
                    </div>
                    
                    <p class="news-summary">On top of 348 known job cuts across the organization last year, Genentech laid off an additional 141 staffers last August that are just now being disclosed.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/genentech-cut-least-489-jobs-last-year-new-disclosure-reveals" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biogen pins SMA recovery on high-dose Spinraza amid projected 2026 revenue slump
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-06 11:32</span>
                        
                    </div>
                    
                    <p class="news-summary">Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees positive signs with the recent launch of its high-dose version of the spinal muscular atrophy treatment in Japan.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/biogen-counting-upcoming-fda-decision-hd-spinraza-reverse-sales-slide" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BridgeBio shares slide as Pfizer&#39;s tafamidis patent revoked in Europe
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-06 10:10</span>
                        
                    </div>
                    
                    <p class="news-summary">The stock price of BridgeBio plunged 15% Thursday on Pfizer&#39;s reported decision to withdraw a tafamidis patent in the EU, triggering fears of earlier generic entry in the blockbuster ATTR-CM market.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/bridgebio-shares-slide-amid-pfizer-reported-decision-withdraw-vyndamax-eu-patent" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The biggest potential drug launches of 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 15:34</span>
                        
                    </div>
                    
                    <p class="news-summary">On this weekâ€™s &#34;The Top Line,&#34; Fierceâ€™s Andrea Park and Gabrielle Masson dive into the most anticipated drug launches of 2026 and the blockbuster sales potential shaping biopharmaâ€™s next wave.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/biggest-potential-drug-launches-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UPDATE: TrumpRx, US government&#39;s cash-pay drug purchasing portal, has arrived
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 14:31</span>
                        
                    </div>
                    
                    <p class="news-summary">Thursday evening, President Donald Trump debuted TrumpRx, a government-run website that directs patients toward cash-pay channels where they can purchase certain prescription drugs.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trumprx-governments-cash-pay-drug-purchasing-tool-primed-launch" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Merz steps into the ring with Muhammad Ali-inspired Inbrija campaign
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-05 07:41</span>
                        
                    </div>
                    
                    <p class="news-summary">Merz Therapeutics has launched a punchy marketing campaign for Parkinsonâ€™s disease drug Inbrija, working Muhammad Ali quotes and footage into a revised version of the medâ€™s â€œFor the Fightersâ€ initiative.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/merz-steps-ring-muhammad-ali-inbrija-campaign" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sun Pharma marks Super Bowl â€˜SUNdayâ€™ with skin cancer awareness drive
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 14:53</span>
                        
                    </div>
                    
                    <p class="news-summary">For Sun Pharma, every dayâ€”from Super Bowl Sunday and beyondâ€”is â€œSUNday.â€</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/sun-pharma-marks-super-bowl-sunday-skin-cancer-awareness-drive" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novartis CEO projects 2026 growth despite â€˜largest patent expiryâ€™ in company history
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-02-04 13:40</span>
                        
                    </div>
                    
                    <p class="news-summary">Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmakerâ€™s fourth-quarter results start to show the impact of the â€œlargest patent expiryâ€ in its history.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novartis-ceo-projects-2026-growth-despite-largest-patent-expiry-company-history" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-06 22:59</span>
                        
                    </div>
                    
                    <p class="news-summary">STAT analysis: Many of the prescription drugs on TrumpRx are available elsewhere as cheaper generics.</p>
                    
                    <a href="https://www.statnews.com/2026/02/06/trumprx-discount-drug-website-undercut-by-cheaper-generics/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: White House looks for more drug pricing deals to add to TrumpRx
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-06 18:36</span>
                        
                    </div>
                    
                    <p class="news-summary">The Trump administration wants more companies to offer prescription drugs at discounted cash prices on TrumpRx.</p>
                    
                    <a href="https://www.statnews.com/2026/02/06/white-house-wants-more-pharma-companies-on-trumprx/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-06 16:11</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/06/pharma-biotech-jobs-astrazeneca-novo/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about TrumpRx, Hims &amp; Hers selling compounded Wegovy pill, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-06 14:21</span>
                        
                    </div>
                    
                    <p class="news-summary">President Trump on Thursday night launched TrumpRx, the website he and his aides have touted as a platform aimed at lowering drug prices</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/06/trump-hims-wegovy-novo-obesity-cvs-340b-fda/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Statins donâ€™t cause most of the side effects on package warnings, study finds
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 23:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Many people who should be taking statins avoid them for fear of side effects. A large new study says most of those side effects don&#39;t actually show up.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/statin-side-effects-evidence-lacking-lancet-study-says/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo Nordisk accuses Hims &amp; Hers of â€˜illegal mass compoundingâ€™ over a cheaper version of Wegovy pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 20:51</span>
                        
                    </div>
                    
                    <p class="news-summary">Hims &amp;#38; Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of â€œillegal&amp;#8230;</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/05/novo-weight-obesity-wegovy-hims-compounding-telehealth/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What to know about TrumpRx, the Trump administrationâ€™s prescription drug platform
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 18:00</span>
                        
                    </div>
                    
                    <p class="news-summary">On Thursday, President Trump launched TrumpRx, the website he and his aides have touted for months as a platform aimed at lowering prescription drug prices.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/trumprx-what-to-know-drug-prices/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo and Lilly both see price cuts as helpful for long-term gain
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 14:36</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/biotech-news-novo-and-lilly-price-cuts-for-gain/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Opinion: TrumpRx has a fundamental flaw
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">The real winners from TrumpRx are pharmaceutical manufacturers.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/trumprx-prescription-drug-costs-flaws/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Vertexâ€™s CRISPR treatment for sickle cell disease hits unexpected roadblock
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-05 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Vertex is running out of time to establish Casgevy as a transformative treatment for sickle cell.</p>
                    
                    <a href="https://www.statnews.com/2026/02/05/vertex-crispr-sickle-cell-treatment-casgevy-faces-rollout-bottleneck/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: FTC settles lawsuit with Express Scripts over charges it manipulated insulin prices, impeded access
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 18:07</span>
                        
                    </div>
                    
                    <p class="news-summary">The FTC settled a lawsuit against Express Scripts over allegations that the company artificially inflated the price of insulin and impeded access to treatment.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/02/04/pbm-cigna-express-scripts-ftc-insulin-settlement-rebates/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer defends data on Metsera candidate
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-04 14:44</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by the Readout Newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/02/04/biotech-news-pfizer-defends-metsera-data/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo Nordisk sees lower sales, profits as Wegovy faces growing competition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 17:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/novo-nordisk-lowers-sales-profit-forecast/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pfizer unveils data on Metsera drug
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-02-03 14:41</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/02/03/biotech-news-pfizer-unveils-data-on-metsera-drug/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Oncology (Cancer)/Hematologic Malignancies Approval Notifications
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:46</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA does not&amp;nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&amp;nbsp;Drugs@FDA&amp;nbsp;for the latest approvals and prescribing information for specific products.</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        List of Determinations Including Written Request
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:49</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/list-determinations-including-written-request" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Untitled Letters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 20:49</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion&#39;s untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.</p>
                    
                    <a href="http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Registered Outsourcing Facilities
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 16:42</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Discover FDA&#39;s comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 15:15</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:46</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:44</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The U.S. Food and Drug Administration (FDA) is providing this communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. All healthcare providers sho</p>
                    
                    <a href="http://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Cefiderocol Injection
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 17:07</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Cefiderocol Injection - FDA Identified Interpretive Criteria</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/cefiderocol-injection" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Notices of Updates
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 17:04</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Webpage providing notices of updates to FDA&#39;s STIC webpages for antibacterial and antifungal drugs.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/notices-updates" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Newly Added Guidance Documents
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 16:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Guidance documents represent the FDA&#39;s current thinking on a particular subject. New guidance documents are listed here for three months.</p>
                    
                    <a href="http://www.fda.gov/drugs/guidances-drugs/newly-added-guidance-documents" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 22:40</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots: LEROCHOL
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 18:29</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: LEROCHOL</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lerochol" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CDER Small Business and Industry Assistance (SBIA) Learn
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 17:01</span>
                        
                    </div>
                    
                    <p class="news-summary">SBIA Learn offers a variety of multimedia resources to provide information that is comprehensive, interactive, and easily accessible to small pharmaceutical business and industry.</p>
                    
                    <a href="http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/cder-small-business-and-industry-assistance-sbia-learn" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        E22 General Considerations for Patient Preference Studies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 13:11</span>
                        
                    </div>
                    
                    <p class="news-summary">E22 General Considerations for Patient Preference Studies</p>
                    
                    <a href="http://www.fda.gov/regulatory-information/search-fda-guidance-documents/e22-general-considerations-patient-preference-studies" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Search for Regulatory References | Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-06 00:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Find information on drug development, applications, submissions, manufacturing &amp;amp; quality, safety, labeling and more</p>
                    
                    <a href="http://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/search-regulatory-references-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Recently Issued Guidance Documents
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 19:30</span>
                        
                    </div>
                    
                    <p class="news-summary">This page lists Recently Issued CBER and Cross-Center Guidance Documents.</p>
                    
                    <a href="http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        National Drug Code Directory
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 18:59</span>
                        
                    </div>
                    
                    <p class="news-summary">National Drug Code Directory</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Electronic Registration and Listing Compliance Program
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 18:59</span>
                        
                    </div>
                    
                    <p class="news-summary">Establishment registration and drug listing data is submitted by drug manufacturers and own label drug distributors through electronic means using Structured Product Labeling format (SPL).</p>
                    
                    <a href="http://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/electronic-registration-and-listing-compliance-program" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 18:28</span>
                        
                    </div>
                    
                    <p class="news-summary">INFORMED CONSENT TEMPLATE FOR INDIVIDUAL PATIENT EXPANDED ACCESS</p>
                    
                    <a href="http://www.fda.gov/news-events/expanded-access/informed-consent-template-individual-patient-expanded-access" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Antibacterial Susceptibility Test Interpretive Criteria
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-02-05 17:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Antibacterial Susceptibility Test Interpretive Criteria</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/antibacterial-susceptibility-test-interpretive-criteria" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">9 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        En Carta Diagnosticsâ€™ EC Pocket Lyme test receives FDA Breakthrough Device Designation
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:18</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The US sees around 476,000 new Lyme cases every year</p>
                    
                    <a href="https://pharmatimes.com/news/en-carta-diagnostics-ec-pocket-lyme-test-receives-fda-breakthrough-device-designation/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Patient-centric oncology trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-05 11:35</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Data-driven, patient-first: using insights in striving to transform cancer care</p>
                    
                    <a href="https://pharmatimes.com/thought_leadership/patient-centric-oncology-trials/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IBSA UK&amp;I launches Perovial for the treatment of acute Peyronieâ€™s disease
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronieâ€™s disease</p>
                    
                    <a href="https://pharmatimes.com/news/ibsa-uki-launches-perovial-for-the-treatment-of-acute-peyronies-disease/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-06">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Guesswork to guidance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-06 12:22</span>
                        
                    </div>
                    
                    <p class="news-summary">What content do HCPs value most for their patient care?</p>
                    
                    <a href="https://pharmatimes.com/thought_leadership/guesswork-to-guidance/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-05">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Connect more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-05 11:42</span>
                        
                    </div>
                    
                    <p class="news-summary">Redefining the future of customer relationships in biopharma</p>
                    
                    <a href="https://pharmatimes.com/thought_leadership/connect-more/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Thomas Farrell
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-04 09:48</span>
                        
                    </div>
                    
                    <p class="news-summary">NanoSyrinx has appointed Thomas Farrell as CEO and Director</p>
                    
                    <a href="https://pharmatimes.com/appointments/thomas-farrell/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-04">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ahmed Moussa
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-04 09:42</span>
                        
                    </div>
                    
                    <p class="news-summary">Ahmed Moussa is the new Sanofi Country Lead for UK &amp;#038; Ireland</p>
                    
                    <a href="https://pharmatimes.com/appointments/ahmed-moussa/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-03">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-03 12:43</span>
                        
                    </div>
                    
                    <p class="news-summary">The company will initially develop a vaccine to tackle colorectal and pancreatic cancers</p>
                    
                    <a href="https://pharmatimes.com/news/kahimmune-therapeutics-enters-licensing-agreement-with-gustave-roussy-and-satt-paris-saclay/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-02-02">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ALKâ€™s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-02-02 14:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys</p>
                    
                    <a href="https://pharmatimes.com/news/alks-eurneffy-receives-positive-chmp-opinion-for-emergency-anaphylaxis-treatment-in-children/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-02-07 04:07</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>